BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:
JMP Securities Healthcare Focus conference
Cowen & Co. 12 th Annual Therapeutics Conference
Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' (AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes -- a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August.
Third-quarter earnings: Johnson & Johnson (JNJ) (before market open) and Gilead Sciences (GILD - Get Report) (after market close.) Oct. 14
The FDA's Peripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' (ACOR - Get Report) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec (BIIB) is Acorda's marketing partner for Amaya.
Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here.
Third-quarter earnings: Abbott Labs (ABT) (before market open.) Oct. 15
Third-quarter earnings: Cubist Pharmaceuticals (CBST) (after market closes.) Oct. 16-21
The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's (PFE - Get Report) CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' (RIGL) R788 in rheumatoid arthritis Oct. 19
FDA approval decision date for Amgen's (AMGN) osteoporosis drug denosumab. If approved, Amgen will market the drug under the brand name Prolia. Oct. 22
FDA's approval decision date for Acorda's drug Amaya. Oct. 24-28
The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' (ARNA - Get Report) lorcaserin, Vivus' (VVUS - Get Report) Qnexa and Orexigen Therapeutics' (OREX) Contrave.